JJ
RAPP

Johnson & Johnson’s Rapport Therapeutics RAPP Stock Holding History

Johnson & Johnson’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.4M Hold
1,784,517
– – 9.31% 4
2026
Q1 		$55.8M Hold
1,784,517
– – 8.56% 4
2025
Q4 		$54.1M Hold
1,784,517
– – 9.75% 3
2025
Q3 		$53M Sell
1,784,517
-713,534
-29% -$12.7M 10.52% 4
2025
Q2 		$28.6M Hold
2,498,051
– – 8.55% 3
2025
Q1 		$25.1M Hold
2,498,051
– – 7.33% 5
2024
Q4 		$44.3M Hold
2,498,051
– – 11.48% 3
2024
Q3 		$51.2M Hold
2,498,051
– – 11.97% 2
2024
Q2 		$58.1M Buy
+2,498,051
New +$57.8M 14.5% 2

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Johnson & Johnson's RAPP Position: Q2 2026 in Review

Johnson & Johnson held its Rapport Therapeutics (RAPP) position steady in Q2 2026 at 1,784,517 shares worth $74.4M. The position accounts for 9.31% of the portfolio, ranked #4.

Johnson & Johnson first reported a position in RAPP in Q2 2024 and has held it in 9 quarters since. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Johnson & Johnson held 1,784,517 shares of Rapport Therapeutics worth $74.4M as of Q2 2026.
  • Johnson & Johnson left its Rapport Therapeutics share count unchanged in Q2 2026.
  • Rapport Therapeutics made up 9.31% of Johnson & Johnson's portfolio in Q2 2026, its #4 holding.
  • Johnson & Johnson first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Johnson & Johnson's 13F filing for Q2 2026, filed 6 Aug 2026.